International consortium for better understanding of non-compaction cardiomyopathy

International Consortium for Multimodality Phenotyping in Adults With Non-compaction

Observational Stanford University · NCT04424030

This study is trying to better understand non-compaction cardiomyopathy in adults by looking at their heart health and genetics to improve care and prevention for patients.

Quick facts

Study typeObservational
Enrollment600 (estimated)
Ages18 Years and up
SexAll
SponsorStanford University Academic / other
Locations5 sites (Palo Alto, California and 4 other locations)
Trial IDNCT04424030 on ClinicalTrials.gov

What this trial studies

This study aims to improve the care of adults diagnosed with non-compaction cardiomyopathy (NCCM) by conducting a comprehensive analysis of clinical, genetic, structural, and functional data. The consortium will perform in-depth phenotyping using echocardiography, magnetic resonance imaging (MRI), and computed tomography (CT) to enhance risk stratification for patients. By differentiating between pathological and benign patterns of non-compaction, the study seeks to provide better preventive measures for this heterogeneous disorder. The research will involve a large cohort of adult patients with suspected NCCM, following them over time to gather valuable data.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with hypertrabeculation of the left ventricle meeting specific echocardiographic criteria for NCCM.

Not a fit: Patients with complex congenital heart disease, neuromuscular disorders, or those unable to undergo MRI may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved risk assessment and management strategies for patients with non-compaction cardiomyopathy.

How similar studies have performed: Other studies have shown promise in using multimodal imaging and genetic analysis for similar cardiac conditions, indicating a potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ≥18 years old
* Hypertrabeculation of the left ventricle fulfilling the echo-based Jenni criteria of NCCM
* Clinical cardiac MRI examination performed or planned

Exclusion Criteria (general cohort):

* Complex congenital disease (including transposition great arteries, tetralogy of Fallot, tricuspid atresia, truncus arteriosis, single ventricle, hypoplastic left heart, pulmonary atresia, double-outlet RV), neuromuscular disorders or isolated RV non-compaction
* Inability to provide informed consent
* Contra-indications to MRI, which apply if the clinical cardiac MRI has not yet been performed at the time of study enrollment: permanent pacemakers/ICDs, MRI contrast medium allergy, significant arrhythmia with highly irregular RR intervals, severe dyspnea with inability to lay flat/breath hold, inability to communicate with the MRI technician or follow commands for any reason (psychosis, agitation, etc.), other site-specific contra-indications to clinical MRI of the heart.

Exclusion Criteria (cardiac CT examination):

* Age \<21 years
* Decompensated heart failure, or otherwise clinically unstable
* BMI\>40 kg/m2
* Pregnancy (or cannot be ruled out)
* Known iodine contrast medium allergy
* Kidney dysfunction: eGFR\<45 ml/min
* Thyroid disease: toxic multinodular goiter, Graves' disease, Hashimoto's thyroiditis

Where this trial is running

Palo Alto, California and 4 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Non-Compaction CardiomyopathyEchocardiographyMagnetic resonance imagingComputed tomographyPrognosisGenetics
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.